BioCentury | Jun 1, 2018
Clinical News

Gilead's Epclusa approved in China for HCV

...include Daklinza daclatasvir and Sunvepra asunaprevir from Bristol-Myers Squibb Co. (NYSE:BMY); Viekirax ombitasvir/paritaprevir/ritonavir and Exviera dasabuvir...
BioCentury | May 30, 2018
Company News

Gilead's Epclusa approved in China for HCV

...include Daklinza daclatasvir and Sunvepra asunaprevir from Bristol-Myers Squibb Co. (NYSE:BMY); Viekirax ombitasvir/paritaprevir/ritonavir and Exviera dasabuvir...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Dec 2, 2017
Strategy

Opening the gates in China

...These include Daklinza daclatasvir and Sunvepra asunaprevir from Bristol-Myers Squibb Co.; Viekirax ombitasvir/paritaprevir/ritonavir and Exviera dasabuvir...
...According to ClinicalTrials.gov, Phase III studies in China of BMS’s Daklinza and AbbVie’s Technivie and Exviera...
...provide details on the genotypes for which Olysio was approved. AbbVie’s regimen of Viekirax plus Exviera...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

...Selected 3Q regulatory setbacks. Company Approval AbbVie Inc. (NYSE:ABBV) China approves Viekirax ombitasvir/paritaprevir/ritonavir plus Exviera dasabuvir...
BioCentury | Sep 29, 2017
Clinical News

China approves HCV drugs from Gilead and AbbVie

...79 other countries. Separately, AbbVie Inc. (NYSE:ABBV) told BioCentury that Viekirax ombitasvir/paritaprevir/ritonavir plus Exviera dasabuvir (ABT-333...
...NS5A protein inhibitor, paritaprevir, an HCV NS3/4A protease inhibitor, and ritonavir, an HIV protease inhibitor. Exviera...
...Ill. Product: Sovaldi sofosbuvir (GS-7977) (formerly PSI-7977); Viekirax ombitasvir/paritaprevir/ritonavir plus Exviera dasabuvir (ABT-333) Business: Infectious Chris Lieu dasabuvir Exviera ombitasvir/paritaprevir/ritonavir sofosbuvir Sovaldi Viekirax AbbVie...
BioCentury | Sep 25, 2017
Company News

Gilead's Sovaldi gets Chinese approval

...Also on Monday, AbbVie Inc. (NYSE:ABBV) told BioCentury that Viekirax ombitasvir/paritaprevir/ritonavir plus Exviera dasabuvir (ABT-333...
...NS5A protein inhibitor, paritaprevir, an HCV NS3/4A protease inhibitor, and ritonavir, an HIV protease inhibitor. Exviera...
BioCentury | Dec 15, 2016
Clinical News

Direct-acting antivirals regulatory update

...DAAs marketed in the EU for HCV infection include Daklinza daclatasvir from Bristol-Myers Squibb; Exviera dasabuvir...
...sofosbuvir/velpatasvir; Exviera dasabuvir; Harvoni ledipasvir/sofosbuvir; Olysio simeprevir; Sovaldi sofosbuvir; Viekirax ombitasvir/paritaprevir/ritonavir; Zepatier elbasvir/grazoprevir Business: Infectious Alicia Parker daclatasvir Daklinza dasabuvir elbasvir/grazoprevir Epclusa Exviera Harvoni ledipasvir/sofosbuvir Olysio ombitasvir/paritaprevir/ritonavir simeprevir sofosbuvir sofosbuvir/velpatasvir Sovaldi Viekirax Zepatier AbbVie...
BioCentury | Oct 4, 2016
Company News

FDA adds warning to HCV drugs' labels

...and Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD); Technivie ombitasvir/paritaprevir/ritonavir and Viekira Pak ombitasvir/paritaprevir/ritonavir plus dasabuvir...
BioCentury | Oct 3, 2016
Clinical News

Exviera dasabuvir: Phase IIIb data

...chronic HCV genotype 1b infection without cirrhosis showed that once-daily Viekirax ombitasvir/paritaprevir/ritonavir plus twice-daily Exviera dasabuvir...
...and 1 patient discontinued the study due to noncompliance. A 12-week regimen of Viekirax plus Exviera...
...Mass.) (see BioCentury, Dec. 18, 2006). AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Exviera dasabuvir ( ABT-333...
Items per page:
1 - 10 of 180